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INTRODUCTION
Branch retinal vein occlusion (BRVO) is the second most 
common retinal sight-threatening vascular disorder, the fre-
quency of which is surpassed only by diabetic retinopathy 
(1-3). The occlusion usually develops in an arteriovenous 
nicking, where both vessels share the adventitia. The vi-
sual acuity (VA) decreases because of concurrent retinal 
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PurPose. To evaluate intravitreal bevacizumab (IVB) combined with grid laser photocoagulation in mac-
ular edema (ME) secondary to branch retinal vein occlusion (BRVO).
Methods. Eight eyes (8 patients) with ME associated with BRVO with at least 3 months of evolution 
since symptom onset were included. All subjects underwent measurement of best-corrected visual 
acuity (BCVA) and imaging with spectral domain optical coherence tomography (SD-OCT) at baseline 
and 1, 3, 6, and 12 months. Intravitreal bevacizumab was administered at baseline and macular grid 
laser photocoagulation 1 month later. During follow-up, additional IVB was administered based on 
physician discretion if persistent or recurrent intraretinal fluid (cysts) was observed on SD-OCT. The 
mean BCVA and SD-OCT central subfield thickness (CST) values were determined at each time point. 
Fisher exact test was performed to assess differences between baseline and post-treatment BCVA 
and SD-OCT measurements.
results. The mean baseline BCVA was 0.28±0.14 (mean ± SD), and the mean CST was 479±137 μm. 
The mean BCVAs at 1, 3, 6, and 12 months were 0.47±0.18 (p=0.031), 0.56±0.50 (p=0.031), 0.65±0.60 
(p=0.008), and 0.66±0.65 (p=0.016), respectively. The mean CST values at 1, 3, 6, and 12 months were 
295±60 μm (p=0.008), 333±114 μm (p=0.070), 339±80 μm (p=0.008), and 335±109 μm (p=0.008). 
A mean 2.13 injections were administered; the second injection was administered a mean of 2.71 
months after baseline.
ConClusions. Combined treatment with IVB and macular grid photocoagulation provided good results 
and may be considered as an alternative therapy for ME in BRVO. Further studies are needed to as-
sess these preliminary results.
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hemorrhages, macular ischemia, and macular edema (ME), 
which is the most frequent factor that affects vision in the 
short, intermediate, and especially long term. 
Several therapeutic approaches have been proposed for 
BRVO ranging from isovolemic hemodilution to vitrectomy 
(4-10). Since publication of the Branch Vein Occlusion 
Study Group results in 1984, in which investigators found a 
significant mean improvement of 1.33 lines of vision com-
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metamorphopsia or decreased VA ranging from 0.1 to 0.5 
assessed with 6-meter Snellen charts. All patients had mul-
tiple hemorrhages in the affected BRVO areas and ME as-
sessed by spectral domain optical coherence tomography 
(SD-OCT) (fig. 1). The Ethics Committee of our hospital 
approved the study, which was conducted in accordance 
with the tenets of the Declaration of Helsinki. All patients 
provided informed consent before entering the study. 
At the first visit, all patients underwent a standard ophthal-
mic evaluation of best-corrected visual acuity (BCVA) with 
6-meter Snellen charts and SD-OCT imaging with a macular 
cube 256 × 128 scan protocol (Cirrus HD-OCT®, Carl Zeiss 
Meditec, Dublin, CA, USA). The tomographic parameter an-
alyzed in this study was the central subfield thickness (CST), 
which was measured at baseline and 1, 3, 6, and 12 months 
after treatment (fig. 2). The main outcome measures were 
BCVA and CST for all visits during the study period.
Intravitreal injections of 1.25 mg of bevacizumab (Avastin®, 
Genentech Inc., South San francisco, CA, USA) in a 0.05-
mL volume were administered in the clinic. After instilling 
0.5% proparacaine hydrochloride topical eyedrops 3 times 
every 5 minutes for topical anesthesia, the eye was irrigat-
pared with 0.23 line in controls after 3 years of follow-up 
with a level of evidence A, grid laser photocoagulation has 
been considered the gold standard for treating ME in pa-
tients with BRVO (6). Recently, alternative therapies, i.e., 
intravitreal injections of corticosteroids, anti-vascular en-
dothelial growth factor (VEGf) drugs, or new devices for 
extended drug release such as dexamethasone implants, 
have been proposed, sometimes in combination treatment 
protocols that have not provided definitive medium- and 
long-term results. We propose a previously unreported al-
ternative treatment based on combination treatment with 
intravitreal antiangiogenic therapy and macular grid laser 
photocoagulation of the affected areas in a series of pa-
tients with ME associated with BRVO. 
METHODS
Eight eyes of 8 patients with ME secondary to BRVO and 
decreased VA were prospectively included between May 
and November 2008. Every patient had had at least 3 
months of evolution since symptom onset, described as 
Fig. 1 - Case 3. (A) Baseline color fundus photograph. Multiple hem-
orrhages and venous tortuosity are seen along the occluded vein 
area. The foveal area appears to be affected. A macroaneurysm is 
also present with associated preretinal hemorrhage. (B) Spectral 
domain optical coherence tomography (SD-OCT) at baseline shows 
macular edema with intraretinal cysts in the inner retinal layers. (C, 
D) Baseline intermediate (C) and late-phase (D) fluorescein angiog-
raphy angiograms show macular edema in the fundus and the foveal 
center, with intraretinal cysts in this area assessed by SD-OCT. The 
best-corrected visual acuity has decreased to 0.1. 
Fig. 2 - Case 5. (A) Baseline spectral domain optical coherence 
tomography. The best-corrected visual acuity (BCVA) is 0.3. (B-D) 
Spectral domain optical coherence tomography images at 1, 3, and 
12 months after treatment. The first injection resolved the swelling of 
the macular area and grid laser was performed 1 month later. Spec-
tral domain optical coherence tomography at the third month visit 
shows fluid recurrence. Another dose of bevacizumab is required, 
and 12 months after the first injection the retina appears flat with 
isolated hyporeflective foci, no signs of swelling, and a good visual 
outcome (BCVA 0.9).
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center. Laser was applied 1 month after the first IVB injec-
tion in all cases. One patient (case 2) underwent sectorial 
laser photocoagulation at baseline due to peripheral isch-
emia observed on fluorescein angiography. No additional 
macular grid laser photocoagulation was performed during 
follow-up in any case. 
Statistical analysis was performed with SPSS 15.0 sof-
tware (SPSS Inc., Chicago, IL, USA). fisher exact test was 
used to assess baseline and post-treatment differences in 
VA and central subfield thickness (CST) at all time points. 
The significance level was p≤0.05.
RESULTS
The mean patient age was 71.6±7.68 (mean ± standard 
deviation) years. The demographic features and individual 
patient data are shown in Table I. The mean baseline BCVA 
ed with 5% povidone iodine, opened using a lid retractor, 
and the drug was injected through the pars plana 3.0 mm 
posterior to the limbus in pseudophakic eyes and 3.5 mm 
posterior to the limbus in phakic eyes using a 30-gauge 
needle. After every intravitreal injection, an ophthalmic so-
lution of topical ofloxacin (Exocin®, Allergan Pharmaceu-
ticals Ltd., Ireland) was administered 4 times daily for 1 
week. Intravitreal bevacizumab (IVB) injections were ad-
ministered at baseline in all patients; reinjections were ad-
ministered if persistent or recurrent intraretinal fluid (cysts) 
was observed in SD-OCT.
Laser application was performed with a pan-funduscopic 
TransEquator® lens (Volk Optical Inc., Mentor, OH, USA) 
(spot diameter, 50 µm; exposure time, 200 ms; power, 80-
100 mW) until soft whitening of the retina became appar-
ent, according to physician discretion. Grid laser photoco-
agulation was performed over the area of ME. Laser spots 
were not applied a minimum of 500 µm from the foveal 
TABLE I - DEMOGRAPHICS AND INDIVIDUAL fEATURES Of INCLUDED PATIENTS
Case Age, 
y
Sex Best-corrected visual acuity Central subfield thickness Doses Months
2nd injection
Baseline 1 mo 3 mo 6 mo 12 mo Baseline 1 mo 3 mo 6 mo 12 mo
1 76 M 0.4 0.7 0.8 0.8 0.8 545 190 182 370 305 1 —
2 79 f 0.15 0.4 0.6 0.6 0.7 494 346 327 304 221 2 3
3 63 M 0.10 0.4 0.4 0.4 0.5 737 236 362 370 393 2 3
4 74 f 0.4 0.6 0.4 0.8 0.8 361 281 359 355 311 2 3
5 62 f 0.3 0.7 0.9 0.9 0.9 362 292 253 249 251 2 3
6 73 M 0.5 0.5 0.5 0.6 0.5 497 371 560 348 461 2 3
7 64 f 0.2 0.2 0.5 0.5 0.5 534 341 378 486 515 4 1
8 82 M 0.2 0.3 0.4 0.6 0.6 305 304 247 230 230 2 3
Mean 71.63 — 0.28 0.47 0.56 0.65 0.66 479.38 295.13 333.50 339.00 335.88 2.13 2.71
SD 7.68 — 0.14 0.18 0.19 0.16 0.15 137.52 60.10 114.45 80.24 109.66 0.83 0.75
Demographics and individual features of patients included in the study. Best-corrected visual acuity and central subfield thickness assessed by spectral domain 
optical coherence tomography at baseline, month 1, month 3, month 6, and month 12 post-treatment; total number of intravitreal bevacizumab (IVB) doses per eye 
and months post-treatment in which 2nd dose of IVB was performed (if required). 
TABLE II -  MEAN BEST-CORRECTED VISUAL ACUITY AND MEAN CENTRAL SUBfIELD THICKNESS AT DIffERENT TIME-
POINTS
Mean best-corrected visual 
acuity 
p Mean central subfield 
thickness
p
Baseline 0.28 479.38
1 mo 0.47 0.031* 295.13 0.008*
3 mo 0.56 0.031* 333.50 0.070
6 mo 0.65 0.008* 339.00 0.008*
12 mo 0.66 0.016* 335.88 0.008*
Mean best-corrected visual acuity and mean central subfield thickness assessed by spectral domain optical coherence tomography at baseline, month 1, month 3, 
month 6, and month 12 post-treatment. *p≤0.05.
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ment for ME in patients with BRVO. In the current study, a 
gain of 2 lines of vision was observed at 8 months in 65% of 
patients; that increase was 1.3 lines 3 years after laser ap-
plication (6). These results have not been clearly surpassed 
by other treatments in comparably designed studies. 
Several authors have considered surgery as a treatment 
for ME associated with BRVO. Pars plana vitrectomy with 
posterior hyaloidectomy and sheathotomy of the arterio-
venous nicking resolved the ME in different series (7-9). 
Whereas the technical difficulty of the surgery was the main 
limitation, other authors have suggested that sheathotomy 
was unnecessary and showed similar results in a compara-
tive study (10). Nevertheless, the inherent inconvenience 
of surgery and the limited surgical results have shifted the 
focus to other less-invasive therapies.
The development of pharmacologic intravitreal treatment 
has been remarkable in recent years, and these drugs cur-
rently are used routinely to treat diverse retinal pathologies. 
Intravitreal injection of corticosteroids, especially triamci-
nolone acetonide (TA), has been widely used to treat ME 
with diverse etiologies, including BRVO. Several authors 
have reported good short- and intermediate-term VA re-
sults with TA (11-15). Unfortunately, these studies had 
small numbers of patients and frequently lacked a control 
group for comparison. The findings cannot be considered 
definitive and larger studies must confirm them. More re-
cently, the Standard Care vs Corticosteroid for Retinal Vein 
Occlusion (SCORE) study, which included a large number 
of patients and a 12-month follow-up period, reported that 
intravitreal injection of TA did not obtain better results than 
those in the control group treated with grid laser photo-
coagulation (16). However, other studies have compared 
TA use combined with grid laser photocoagulation and ob-
tained acceptable results in short series (17, 18), but prob-
lems related to intravitreal administration, i.e., glaucoma, 
cataract development, or noninfectious endophthalmitis, 
and the fact that TA administration is an off-label use, have 
reduced physician interest in this treatment. To overcome 
these problems, new corticosteroid delivery devices have 
been developed. The dexamethasone implant, which was 
approved recently by the food and Drug Administration 
for use in patients with BRVO, has reduced the risk of vi-
sion loss and improved the speed and incidence of visual 
improvement at 6 months compared to sham controls with 
moderate adverse effects (19-21). Although these results 
have been promising, they must be ratified in further re-
ports with longer follow-up periods.
was 0.28±0.14 Snellen, and at 1, 3, 6, and 12 months af-
ter treatment the BCVA levels were 0.47±0.18 (p=0.031), 
0.56±0.50 (p=0.031), 0.65±0.60 (p=0.008), and 0.66±0.65 
(p=0.016), respectively (Tab. II). The mean baseline CST 
was 479±137 µm; 1, 3, 6, and 12 months after treatment 
the mean CST values were 295±60 µm (p=0.008), 333±114 
µm (p=0.070), 339±80 µm (p=0.008), and 335±109 µm 
(p=0.008) (Tab. II). The mean number of injections was 
2.13±0.83. In 7 patients who required a second injection, 
the injection was administered a mean of 2.71 months (SD 
0.75) after the first dose. One patient required 4 injections 
during follow-up, and another patient did not receive ad-
ditional treatment.
DISCUSSION
Intravitreal bevacizumab associated with grid laser photo-
coagulation decreased the CRT assessed by SD-OCT and 
improved the VA in patients with ME secondary to BRVO. 
After the first IVB injection, a decrease in the CRT was ob-
served in all cases associated with an increase in the VA 
before and after grid laser photocoagulation. We did not 
observe the same effect with the second injection admin-
istered at about month 3 of follow-up, 2 months after grid 
laser photocoagulation. Although the CRT did not steadily 
decrease after the second IVB injection, the VA improve-
ment was sustained from the third month through the re-
mainder of the follow-up period. Thus, from the 3-month 
evaluation, we did not find a good correlation between the 
VA and the CRT, which agreed with the results of previous 
studies with a larger number of patients with ME second-
ary to BRVO (1). However, this unexpected discrepancy 
suggested that other factors may be involved, i.e., the in-
tegrity of the junction between the inner and outer photo-
receptor segments on SD-OCT, the volume of intraretinal 
cysts, or retinal pigment epithelium atrophy. Unfortunately, 
assessment of the influence of these factors in our results 
exceeds the limitations of this study. 
The treatment of ME secondary to BRVO has been con-
troversial (2, 3). Ranging from isovolemic hemodilution (4) 
to vitrectomy with sheathotomy (5) of the arteriovenous 
nicking, therapies such as laser grid photocoagulation or 
intravitreal drug injections have not provided definitive sat-
isfactory, evidence-based results. Since the Branch Vein 
Occlusion Study Group published its results in 1984, grid 
laser photocoagulation has been the gold standard treat-
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unknown and several hypotheses have been proposed, we 
consider that the benefit may be due to retinal pigment 
epithelium stimulation. To our knowledge, this is the first 
study to propose this sequential combination treatment in 
a series of patients with ME associated with BRVO. The 
results obtained were promising, but the small number 
of patients, the lack of a control group, and the limited 
12-month follow-up period does not permit us to draw de-
finitive conclusions. However, the results of this study are 
a well-founded basis to develop further studies involving a 
larger number of patients to confirm these results. In con-
clusion, the findings suggested that combination treatment 
comprised of IVB and grid laser photocoagulation may be 
an alternative option for these patients.
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In the last decade, the results achieved with anti-VEGf 
drugs in age-related macular degeneration and the sug-
gested role of VEGf in the development of ME second-
ary to vascular pathologies have led to a hypothesis about 
their effectiveness. Therefore, several studies have been 
performed to assess ranibizumab (Lucentis®, Genentech 
Inc.), bevacizumab, and pegaptanib (Macugen®, Pfizer/
Eyetech Pharmaceutical) on ME in patients with BRVO 
(22-26). Most studies have been uncontrolled, nonrandom-
ized short case series, and it is impossible to make reliable 
comparisons among them. However, Campochiaro and 
the BRAVO Study Group recently reported significant visu-
al improvement with intravitreal ranibizumab compared to 
sham injection at 6 months, with a lower rate of rescue grid 
laser than controls and no increased adverse effects (27). 
The medium- and long-term data of this study will provide 
important information about its role in clinical practice.
The clinical observation that antiangiogenic drugs, specifi-
cally bevacizumab, effectively decreased the ME associat-
ed with BRVO led to the current study. The aim of our study 
was to add a beneficial transient effect over the vascular 
permeability of IVB to the long-term macular stabilization 
provided by grid laser photocoagulation. Although the 
mechanism of this laser-related beneficial effect remains 
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